GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (NAS:GRTX) » Definitions » Price-to-Free-Cash-Flow

Galera Therapeutics (Galera Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-26), Galera Therapeutics's share price is $0.196. Galera Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.80. Hence, Galera Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Galera Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

GRTX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.69
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Galera Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.80.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 25.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.90% per year.

During the past 7 years, Galera Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 50.30% per year. The lowest was -31.50% per year. And the median was 4.75% per year.


Galera Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Galera Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galera Therapeutics Price-to-Free-Cash-Flow Chart

Galera Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Galera Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galera Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Galera Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galera Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Price-to-Free-Cash-Flow falls into.



Galera Therapeutics Price-to-Free-Cash-Flow Calculation

Galera Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.196/-0.795
=N/A

Galera Therapeutics's Share Price of today is $0.196.
Galera Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Galera Therapeutics  (NAS:GRTX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Galera Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Galera Therapeutics (Galera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 134, Malvern, PA, USA, 19355
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its lead product candidate, GC4419, is a small molecule dismutase mimetic developed for the reduction of severe oral mucositis, or SOM.
Executives
Mark Bachleda officer: Chief Commercial Officer C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Mel Sorensen director, officer: President and CEO 7 RAPPS RUN DRIVE, MALVERN PA 19355
Eugene P. Kennedy officer: Chief Medical Officer 2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey officer: See Remarks AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund officer: Chief Medical Officer
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s 10 percent owner, other: SEE REMARKS TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman officer: Chief Accounting Officer C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Clarus Iv-a, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Blackstone Clarus Gp L.p. 10 percent owner C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Sofinnova Venture Partners Ix, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025